SNN - Smith & Nephew plc
43.76 +0.55 (1.27%)
Pre-Market: 6:51AM EST
| Previous Close | 42.89 |
| Open | 43.14 |
| Bid | 43.69 x 800 |
| Ask | 43.33 x 1100 |
| Day's Range | 42.90 - 43.22 |
| 52 Week Range | 35.39 - 48.93 |
| Volume | 296,120 |
| Avg. Volume | 670,784 |
| Market Cap | 18.755B |
| Beta (3Y Monthly) | -0.13 |
| PE Ratio (TTM) | 27.11 |
| EPS (TTM) | 1.59 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.73 (1.70%) |
| Ex-Dividend Date | 2019-10-03 |
| 1y Target Est | 52.50 |
- PR Newswire
Smith+Nephew launches industry-first OR3O™ Dual Mobility System utilising unique OXINIUM™ DH metal alloy for use in primary and revision hip arthroplasty
OXINIUM Technology is the first advanced bearing material available to support modular dual mobility throughout the entire offering LONDON , Nov. 8, 2019 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), ...
- Simply Wall St.
How Much Of Smith & Nephew plc (LON:SN.) Do Institutions Own?
The big shareholder groups in Smith & Nephew plc (LON:SN.) have power over the company. Generally speaking, as a...
- PR Newswire
Accelerate Diagnostics Appoints Roland Diggelmann to its Board of Directors
TUCSON, Ariz., Nov. 4, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced that Roland Diggelmann has been appointed to its Board of Directors. "On behalf of the entire board, I am delighted to welcome Roland to Accelerate Diagnostics," commented John Patience, Chairman of the Board of Directors. "Roland brings extensive experience from his decades of successful diagnostics company leadership.
- Reuters
U.S. patent board is unconstitutional, but problem can be fixed -appeals court
A federal appeals court on Thursday said the structure of the U.S. Patent Trial and Appeal Board is unconstitutional, but the problem can be fixed by severing a portion of federal patent law that restricts the removal of administrative patent judges. The U.S. Federal Circuit Court of Appeals said the impact of its decision would be "limited" to cases in which the board had issued final written decisions, and litigants challenged on appeal the appointment of the board's judges under the U.S. Constitution's Appointments Clause.
- Barrons.com
Shares Fall At Smith & Nephew After CEO’s Surprise Departure, But It’s Just a Blip
Namal Nawana is stepping down as chief executive of Smith & Nephew less than 18 months into the role amid reports of a disagreement over pay.
- Reuters
CORRECTED-UPDATE 2-European shares rise amid Brexit tussle as focus shifts to earnings
European shares broke a three-day run of losses on Monday, as investors stuck to hopes that Britain will avoid a disorderly exit from the European Union, while positive corporate updates and comments on U.S.-China trade talks added to the upbeat mood. The pan-European STOXX 600 index ended the session 0.6% higher, barely budging on news House of Commons speaker John Bercow refused to allow a vote on Prime Minister Boris Johnson's Brexit divorce deal, saying the same issue had been discussed on Saturday.
- Simply Wall St.
The Smith & Nephew (LON:SN.) Share Price Has Gained 86% And Shareholders Are Hoping For More
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses...
- Reuters
Ex-U.S. biotech executive fined for lying to auditors, charges dropped against CFO: SEC
The former chief business officer of U.S. biotechnology company Osiris Therapeutics Inc has agreed to pay a $40,000 civil penalty for lying to auditors, the Securities and Exchange Commission said on Thursday. The SEC had alleged that Bobby Dwayne Montgomery prompted Osiris to book fake revenue and give false information to auditors. Montgomery agreed to a judgment that enjoins him from future violations of securities law, the SEC said in a statement.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Smith & Nephew plc (SNN)
We at Insider Monkey have gone over 730 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of June 28th. In this article, we look at what those funds think of Smith & Nephew plc (NYSE:SNN) based on […]
- Zacks
Smith & Nephew's (SNN) STITCH Study Outcome Encouraging
This can be considered a major step in Smith & Nephew's (SNN) commitment toward strengthening its Global Sports Medicine and ENT segment.
- PR Newswire
Smith+Nephew's NOVOSTITCH™ Meniscal Repair System shows 91.7% success rate in "STITCH" Study at one-year follow-up
LONDON , Oct. 9, 2019 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce results for its NOVOSTITCH Meniscal Repair System today at the International ...
- American City Business Journals
Cover story: The MVP of Memphis VC has invested $120M in 50 startups over two decades
“You’re not going to find a whole lot of other funds in the Southeast that have [a musculoskeletal focus]. … And, there’s not a life sciences industry to speak of in Nashville or even Atlanta.”
- Simply Wall St.
Here's What We Like About Smith & Nephew plc (LON:SN.)'s Upcoming Dividend
Smith & Nephew plc (LON:SN.) is about to trade ex-dividend in the next 2 days. If you purchase the stock on or after...
- PR Newswire
Smith+Nephew introduces ground-breaking assurance program for TRIGEN™ INTERTAN™ Intertrochanteric Hip Fracture Nail
Helps protect healthcare systems against reoperation costs for hip fractures LONDON , Sept. 26, 2019 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announced ...
- PR Newswire
Smith+Nephew launches LENS 4K Surgical Imaging System
The LENS 4K System features a Camera Control Unit with an integrated light source, Camera Head, image management options and Tablet Application in a single solution. The latest native 4K 3CMOS Ultra High Definition technology combined with Smith+Nephew's proprietary image and light processing is intended to create impressive color reproduction, image clarity, and depth of field.
- PR Newswire
Smith+Nephew launches PICO™ 7Y in the US, a portable single use negative pressure wound therapy system to treat two wounds simultaneously
LONDON , Sept. 10, 2019 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, is pleased to announce the US launch of the new PICO 7Y Single Use Negative Pressure Wound ...
- Simply Wall St.
What To Know Before Buying Smith & Nephew plc (LON:SN.) For Its Dividend
Is Smith & Nephew plc (LON:SN.) a good dividend stock? How can we tell? Dividend paying companies with growing...
- Zacks
Smith & Nephew (SNN) Hits a 52-Week High: What's Driving It?
Smith & Nephew (SNN) has been gaining from several positive developments of late.
- Simply Wall St.
Is Smith & Nephew (LON:SN.) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- GuruFocus.com
Gains in Knee Replacement Driving Zimmer Biomet Growth
Shares near 52-week high after surpassing 2nd-quarter expectations Continue reading...
- Simply Wall St.
Should Smith & Nephew plc's (LON:SN.) Recent Earnings Decline Worry You?
Examining how Smith & Nephew plc (LON:SN.) is performing as a company requires looking at more than just a years...
- MoneyShow
Smith Nephew SNN- 2019 Top Picks' Mid-Year Update
Nancy Zambell, editor of Wall Street's Best Investments, chose Smith & Nephew plc (SNN) as her top conservative investment idea for 2019. The stock rose 16.5% in the first half of the year. Here's her latest update on the healthcare firm.
